Lurie Cancer Center receives $12.6M merit extension from NCI

Pancreatic cancer finally starts to budge as daraxonrasib doubles overall survival

A note for historians: On April 21, 2026, pancreatic cancer finally began to budge.

June 05, 2026

The story of daraxonrasib is the ultimate hero’s journey
A narrative curve with twists, turns, intrigue, drama—and a blow to a mighty foe

Those of us who have devoted our careers to treating recalcitrant cancers know the heartbreak of walking alongside an individual facing an advanced diagnosis. We not only shoulder the clinical responsibility, but also the emotional weight that accompanies every step of that journey as each patient’s story becomes connected to our own.

June 05, 2026

Vol.52 No.22

By W. Kimryn Rathmell

Political appointees to be inserted into all stages of making research funding awards if OMB rule becomes final

The White House Office of Management and Budget has released a 412-page proposal that inserts political appointees into all stages of reviewing and awarding of federal research grants.

June 05, 2026

Vol.52 No.22

By Paul Goldberg and Claire Marie Porter

At Senate hearing, Brown’s El-Deiry and other witnesses say they were targeted for arguing that mRNA vaccine may be linked to cancer

If you believe in the miraculous healing power of ivermectin, hydroxychloroquine, and the harm from vaccination for HPV and COVID-19, you’ve got a powerful friend in Sen. Ron Johnson (R-WI), chair of the Permanent Subcommittee on Investigations of the Senate Committee on Homeland Security and Governmental Affairs.

June 05, 2026

Vol.52 No.22

By Sara Willa Ernst, Claire Marie Porter and Paul Goldberg

Eric Small, ASCO’s immediate past president, speaks on the toll of toxicity—financial, emotional, physical—in cancer
“Discovery alone is not enough. It’s about what becomes of what we discover. It’s about translation.”

In a poignant keynote punctuated with anecdotes about grief, American Society of Clinical Oncology’s immediate past president Eric Small emphasized that the annual conference is not just about scientific discovery, but about a responsibility to translate discoveries into better outcomes for cancer patients globally.

June 05, 2026

Vol.52 No.22

By Claire Marie Porter

AI in action: MANAscore tool moves closer to clinic

One of the greatest challenges in cancer immunotherapy is finding the rare immune cells, called tumor-reactive T cells, whose job it is to recognize and eliminate tumor cells.

June 05, 2026

Vol.52 No.22

Lurie Cancer Center receives $12.6M merit extension from NCI

YOU MAY BE INTERESTED IN

Pancreatic cancer finally starts to budge as daraxonrasib doubles overall survival

The story of daraxonrasib is the ultimate hero’s journey
A narrative curve with twists, turns, intrigue, drama—and a blow to a mighty foe

Political appointees to be inserted into all stages of making research funding awards if OMB rule becomes final

At Senate hearing, Brown’s El-Deiry and other witnesses say they were targeted for arguing that mRNA vaccine may be linked to cancer

Eric Small, ASCO’s immediate past president, speaks on the toll of toxicity—financial, emotional, physical—in cancer
“Discovery alone is not enough. It’s about what becomes of what we discover. It’s about translation.”

AI in action: MANAscore tool moves closer to clinic

Renew today!

Subscriber content

Never miss an issue!

Login

Lurie Cancer Center receives $12.6M merit extension from NCI

YOU MAY BE INTERESTED IN

Pancreatic cancer finally starts to budge as daraxonrasib doubles overall survival

The story of daraxonrasib is the ultimate hero’s journeyA narrative curve with twists, turns, intrigue, drama—and a blow to a mighty foe

Political appointees to be inserted into all stages of making research funding awards if OMB rule becomes final

At Senate hearing, Brown’s El-Deiry and other witnesses say they were targeted for arguing that mRNA vaccine may be linked to cancer

Eric Small, ASCO’s immediate past president, speaks on the toll of toxicity—financial, emotional, physical—in cancer“Discovery alone is not enough. It’s about what becomes of what we discover. It’s about translation.”

AI in action: MANAscore tool moves closer to clinic

Never miss an issue!

Login

The story of daraxonrasib is the ultimate hero’s journey
A narrative curve with twists, turns, intrigue, drama—and a blow to a mighty foe

Eric Small, ASCO’s immediate past president, speaks on the toll of toxicity—financial, emotional, physical—in cancer
“Discovery alone is not enough. It’s about what becomes of what we discover. It’s about translation.”